Navigation Links
AcelRx Pharmaceuticals Reports Positive Results From a Phase 2 Clinical Trial of Sublingual Sufentanil NanoTabs(TM) in Treating Post-Operative Pain
Date:12/9/2008

REDWOOD CITY, Calif., Dec. 9 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. today announced positive results from a Phase 2 clinical study evaluating the safety and efficacy of its lead product candidate, ARX-01, for the treatment of moderate-to-severe inpatient acute pain following knee replacement surgery. The primary endpoint evaluated pain intensity (Sum of the Pain Intensity Difference - SPID12) over the 12-hour study period compared to baseline. Results demonstrated that compared to placebo, patients receiving 15 mcg of ARX-01 experienced a statistically significant reduction in pain intensity over the study period, based on the worst observation carried forward imputation method (WOCF), p=0.015. Additionally, at the 15 mcg dose, the study met an important secondary endpoint compared to placebo, the percentage of patient dropouts due to inadequate analgesia, p=0.006. Further, no serious or unexpected adverse events related to ARX-01 were reported in the study.

ARX-01 is a sublingual formulation of the opioid pain medication, sufentanil. ARX-01 is based on the company's proprietary NanoTab(TM) dosage form, which enables delivery of sufentanil by the non-invasive oral transmucosal (sublingual) route.

"We chose a very painful surgery in an elderly patient population to showcase the efficacy and safety of Sublingual Sufentanil NanoTabs in treating acute post-operative pain," said Pamela Palmer, M.D., Ph.D., chief medical officer of AcelRx Pharmaceuticals. "The superior attributes of both the drug and the dosage form enabled these highly encouraging Phase 2 results."

This multicenter, double-blind, randomized, placebo-controlled, dose-finding Phase 2 study evaluated the safety and efficacy of ARX-01 in patients undergoing elective unilateral knee replacement surgery. In the study, 101 patients were randomized to receive either placebo or one of three different dosage strengths of ARX-01: 5mcg, 10m
'/>"/>

SOURCE AcelRx Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
2. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
5. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
6. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
7. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
8. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
9. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
10. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
11. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... Calif. (PRWEB) November 20, 2014 ... nonprofit, public policy research organization representing leading California ... firms, and PwC US today released ... in life sciences industry growth. The trend shows ... The 2015 California Biomedical Industry Report ...
(Date:11/21/2014)... 2014 Deep Research Report on ... professional and in-depth research report on the Sodium ... like its definition, classification, application, and industry chain ... covers the international market analysis, including China’s domestic ... US, Europe, Asia, China, Japan etc. regions) industry ...
(Date:11/21/2014)... - BIOREM Inc. (TSXV: BRM) ("Biorem" or "the Company") today announced results ... 2014.  Biorem,s complete 2014 third quarter financial statements and MD&A have ... ended September 30, , Nine-months ended September ... 2014 , 2013 , 2014 , ... , 6,715 , 14,476 Gross profit , ...
(Date:11/18/2014)... Diego, CA (PRWEB) November 17, 2014 Athena ... of Salk , Dr. Beverly Emerson, a professor in the ... of genes. Her most recent discovery points to an “off ... Dr. Emerson’s career and how her local research is making ... will present her findings and then join host Cheryl K. ...
Breaking Biology Technology:California Healthcare Institute and PwC Report Boom in California’s Biomedical Industry 2California Healthcare Institute and PwC Report Boom in California’s Biomedical Industry 3California Healthcare Institute and PwC Report Boom in California’s Biomedical Industry 4Sodium Ferrocyanide Market: Analysis for Global & China Regions Development Trends Available at DeepResearchReports.com 2Sodium Ferrocyanide Market: Analysis for Global & China Regions Development Trends Available at DeepResearchReports.com 3Biorem Reports Third Quarter Results 2Biorem Reports Third Quarter Results 3
... Auxilium Pharmaceuticals, Inc. (Nasdaq: AUXL ), a specialty ... full year 2010 on Thursday, February 10, 2011 before the ... conduct a conference call that day at 10:00 a.m. ET ... full year 2010.  The presentation slides to be used during ...
... Biotechnology and Biomedicine and the UAB Department of Biochemistry ... using Saccharomyces cerevisiae yeast to detect in ... of molecules which can initiate the assembly of amyloid ... the efficacy of compounds which could dissolve or inhibit ...
... Calif., Feb. 2, 2011 Sangamo BioSciences, Inc. (Nasdaq: ... 2010 financial results and accomplishments. For the ... net loss of $8.3 million, or $0.18 per share, compared ... share, for the same period in 2009. As of December ...
Cached Biology Technology:Auxilium Pharmaceuticals to Announce Fourth Quarter and Full Year 2010 Results and Conduct Conference Call on Thursday, February 10, 2011 2Auxilium Pharmaceuticals to Announce Fourth Quarter and Full Year 2010 Results and Conduct Conference Call on Thursday, February 10, 2011 3Auxilium Pharmaceuticals to Announce Fourth Quarter and Full Year 2010 Results and Conduct Conference Call on Thursday, February 10, 2011 4New test to study proteins involved in neurodegenerative diseases 2Sangamo BioSciences Reports Fourth Quarter and Full Year 2010 Financial Results 2Sangamo BioSciences Reports Fourth Quarter and Full Year 2010 Financial Results 3Sangamo BioSciences Reports Fourth Quarter and Full Year 2010 Financial Results 4Sangamo BioSciences Reports Fourth Quarter and Full Year 2010 Financial Results 5Sangamo BioSciences Reports Fourth Quarter and Full Year 2010 Financial Results 6Sangamo BioSciences Reports Fourth Quarter and Full Year 2010 Financial Results 7
(Date:11/5/2014)... professor of biology in the UTSA College of ... nation selected to receive a two-year $300,00 National ... Research (EAGER). The funding supports President Obama,s BRAIN ... create new technology that will demystify complex brain ... in neuroscience are broken into the interactions of ...
(Date:11/4/2014)... Temple University School of Medicine announced today that ... initiative funded by the Bill & Melinda Gates ... Obstetrics, Gynecology and Reproductive Sciences; and Vice Chair ... School of Medicine will pursue an innovative global ... Biomarkers to Assess Fetal Neurodevelopment.", Grand Challenges Explorations ...
(Date:11/4/2014)... 2014   Neurotechnology , a provider of ... latest version of its fingerprint matching algorithm has ... evaluation organized by NIST. The MINEX test ... INCITS 378 fingerprint standard template format. MINEX compliance ... in the United States ...
Breaking Biology News(10 mins):UTSA biology professor awarded $300,000 NSF grant for brain research 2UTSA biology professor awarded $300,000 NSF grant for brain research 3Temple University School of Medicine receives Grand Challenges Explorations grant 2Neurotechnology Places Second in Ongoing MINEX Ranking for Fingerprint Matching Algorithms 2Neurotechnology Places Second in Ongoing MINEX Ranking for Fingerprint Matching Algorithms 3
... Mich.---In the mating game, some female mites are mightier than ... the Russian Academy of Sciences suggests. The evidence comes, in ... In a paper published March 1 in the ... and Ekaterina Sidorchuk describe an extinct mite species in which ...
... look at possible health effects of the Gulf of Mexico,s ... begins today in towns across Louisiana, Mississippi, Alabama, and Florida. ... the largest health study of its kind ever conducted among ... comprehensive federal response to the Deepwater Horizon oil spill. The ...
... University of Maryland School of Medicine researchers have ... open doors to new, more effective treatments for excessive ... in the brain, GABA receptors and toll-like receptor 4 ... weeks in rodents that had been bred and trained ...
Cached Biology News:Mating mites trapped in amber reveal sex role reversal 2NIH launches largest oil spill health study 2University of Maryland School of Medicine study identifies genes associated with binge drinking 2University of Maryland School of Medicine study identifies genes associated with binge drinking 3University of Maryland School of Medicine study identifies genes associated with binge drinking 4
...
... is the first biological reagent ... them, and not just by ... only anti-mycoplasma agent that can ... stocks directly. The cytotoxicity of ...
... can be used to label ... covalently bound acridinium NHS ester ... presence of hydrogen peroxide. Acridinium ... used as a detection method ...
... assay (EMSA) is a powerful tool for ... gel shift or gel retardation, the assay ... subjected to electrophoresis, free DNA will migrate ... LightShift Chemiluminescent EMSA Kit is a nonradioactive ...
Biology Products: